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The anemia of end-stage renal disease: Hematopoietic progenitor cell
response. Patients with the anemia of end-stage renal disease (ESRD)
fail to display an appropriate compensatory increase in red cell produc-
tion. In order to investigate the extent to which the impaired erythro-
poietic response is determined at the progenitor cell level, we deter-
mined the frequencies of marrow colony-forming cells in II anemic and
3 non-anemic, dialysis-dependent ESRD patients and 10 healthy indi-
viduals. In addition, we measured serum levels of erythropoietin (Epo)
by radioimmunoassay. There were no significant differences (P > 0.1)
between normal and ESRD groups in the frequencies of primitive or late
erythroid (BFU-E and CFU-E, respectively), granulocyte-macrophage.
and megakaryocyte progenitors, CFU-E/BFU-E ratios, or serum Epa
levels. In contrast, 5 non-uremic patients with chronic anemia compa-
rable in severity to the anemic ESRD patients had serum Epo levels and
CFU-E/BFU-E ratios that were significantly increased (P < 0.05 and P
<0.001, respectively) in comparison to the normal controls and ESRD
patients. Pre-dialysis serum and plasma from both ESRD groups were
as supportive of autologous erythroid and non-erythroid colony growth
in vitro as normal serum and plasma; inhibition was not observed. We
conclude that the relative numbers of erythroid and non-erythroid
progenitors and the majority of serum Epo levels are unchanged from
normal in patients with the anemia of ESRD. However, their normal
CFU-E/BFtJ-E ratio reflects an inadequate compensatory erythro-
poietic response due to their inability to appropriately increase Epa
production in response to anemia. Inhibitors of autologous erythroid
colony formation were not detected in ESRI) serum. Proof of the
pathogenetic significance of retained inhibitors of erythroid marrow
function in ESRD will likely require in viva studies which directly
compare the acute responses of normal individuals and anemic ESRD
patients to graded doses of infused Epo.
Patients with end-stage renal disease (ESRD) are usually
anemic and fail to display an appropriate compensatory eryth-
ropoietic response to the anemia [I, 2]. It is generally accepted
that impaired renal production of erythropoietin (Epo) is the
primary cause of this blunted marrow response [3, 4]. In
addition, some workers have speculated, on the basis of in vitro
studies and indirect clinical evidence, that retained inhibitors of
erythroid marrow function may contribute to the anemia of
ESRD [5].
In this study, we have measured serum Epo levels and
marrow colony-forming cell frequencies in a group of anemic
ESRD patients and compared these results to the values ob-
served in non-anemic ESRD patients, healthy controls, and a
group of anemic patients with appropriate marrow responses.
We sought to investigate the extent to which the impaired
erythropoietic response in anemic ESRD patients is reflected at
the progenitor cell level. In order to evaluate the potential
significance of retained inhibitors in these patients, we also
have examined the effect of their serum and plasma on eryth-
roid and non-erythroid colony growth in cultures of autologous
marrow cells.
Methods
Study population
The subjects with ESRD evaluated in these studies included
11 patients with chronic anemia (hematocrit 15 to 26%, pre-
dialysis serum creatinine 9.6 to 20.8 mg/dl) and 3 patients who
were not anemic (hematocrit 42 to 43%, pre-dialysis serum
creatinine 11.8 to 17.8 mgldl). All of these patients were
hemodialysis-dependent and had normal white blood cell and
platelet counts. Nephropathologic diagnoses for the anemic
ESRD patients at the time of study included chronic glomeru-
lonephritis (2), nephrosclerosis (2), interstitial nephritis (2),
oxalate nephropathy (1), and tuberous sclerosis (1); three
patients were anephric. The three non-anemic ESRD patients
included two with polycystic renal disease and one with chronic
glomerulonephritis. Two control groups were studied: (1) 10
healthy individuals and (2) 5 non-uremic patients with chronic
anemia (hematocrit 21 to 29%) comparable in severity to the
anemic ESRD patients. Diagnoses in this latter group included
paroxysmal nocturnal hemoglobinuria (2), sickle cell disease
(2), and pyruvate kinase deficiency (I). These studies were
performed with informed consent under a protocol approved by
the Human Subjects Review Committee of the University of
Washington.
Serum and plasma samples
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Overnight fasted blood samples were obtained for the prep-
aration of serum and plasma. Blood samples were obtained
from the ESRD patients just prior to a hemodialysis session. To
prepare serum, the blood was allowed to clot in glass tubes for
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two hours at room temperature and then centrifuged at 2000 g
for 15 minutes. The serum was centrifuged a second time and
the supernatant removed. Aliquots were frozen and stored at
—70° for later determination of Epo levels. For 8 of the anemic
ESRD patients and 6 of the healthy controls, the remaining
serum was sterilized by passage through a 0.45 micron Millipore
filter (Millipore Corporation, Bedford, Massachusetts, USA),
heat-inactivated at 56° for 30 minutes, and frozen and stored at
70° until assayed for inhibitory activity in autologous marrow
cell culture studies. To prepare plasma, the blood was drawn
into plastic syringes containing 10 U/mI preservative-free heparin
(O'Neal, Jones, and Feldman, St. Louis, Missouri, USA) and
centrifuged at 2000 g for 15 minutes. The plasma was centri-
fuged a second time, the supernatant withdrawn and sterilized
by passage through a 0.45 micron Millipore filter, and frozen
and stored at —70° until assayed for inhibitors in marrow culture
studies.
Bone marrow samples
Bone marrow samples were aspirated from the posterior iliac
crest into plastic syringes containing 250 units of preservative-
free heparin and diluted to a final volume of 20 ml in Hanks'
balanced salt solution (Gibco, Grand Island, New York, USA).
Low-density mononuclear cells were isolated by density cen-
trifugation on Ficoll-diatrizoate (1.077 g/ml; LSMR, Litton
Bionetics, Kensington, Maryland, USA) as previously de-
scribed [6]. The cells were suspended to a final concentration of
106/ml in alpha medium (Gibco) supplemented with 10% heat-
inactivated fetal calf serum (FCS, HyClone, Logan, Utah,
USA). Twenty ml volumes of the cell suspension were incu-
bated for two hours in 75 cm2 plastic tissue culture flasks
(Corning Glass Works, Corning, New York, USA) at 37° in 5%
CO2 in air and the non-adherent cells were harvested for use in
colony-forming assays.
Colony-f hrming assays
Hematopoietic colony-forming cells were assayed in methyl-
cellulose culture by previously described methods [6—8]. Eryth-
roid colony-forming cells were assayed by culturing non-adher-
ent marrow cells at a concentration of l05/ml in alpha medium
made semisolid with 1% methylcellulose and supplemented
with 1% deionized bovine serum albumin (Sigma Chemical
Company, St Louis, Missouri, USA), 1 mro l-glutaniine (Gibco),
1O M beta-mercaptoethanol, penicillin-streptomycin, 5% phy-
tohemagglutinin-stimulated peripheral blood leukocyte-con-
ditioned medium (PHA-LCM) [6], and I V/mi human urinary
Epo. One ml volumes were cultured in 35 mm plastic tissue
culture dishes (LuxR, Miles Laboratories, Naperville, Illinois,
USA) at 37° in 5% CO2 in air. Erythroid colonies (derived from
CFU-E) and bursts (from BFU-E) were enumerated after 7 and
13 days in culture, respectively, with an inverted microscope.
Aggregates of 8 or more hemoglobinized cells were scored as
CFU-E-derived colonies. Erythroid bursts were identified as
colonies of at least 200 hemoglobinized cells or as aggregates of
two or more hemoglobinized subcolonies,
Granulocyte-macrophage and megakaryocyte colony-forming
cells (CFU-GM and CFU-Meg, respectively) were assayed by
culturing non-adherent marrow cells at a concentration of
105/ml in Iscove's modified Dulbecco medium (Gibco) made
semisolid with 0.9% methylcellulose and supplemented with
25% normal human plasma (from a single lot), 1 ms'i l-gluta-
mine, 5 >< 10 M beta-mercaptoethanol, penicillin-strepto-
mycin, and 5% PHA-LCM. One ml volumes were cultured for
13 days as above and granulocyte-macrophage and mega-
karyocyte colonies enumerated. Granulocyte-macrophage col-
onies were identified by inverted microscopy as aggregates of
40 or more cells. Megakaryocyte colonies were identified as
aggregates of four or more cells with characteristic refractile
cell membranes and translucent agranular cytoplasm [6].
Epo
The Epo used in these studies was partially purified from the
urine of a patient with pure red cell aplasia, as previously
described [9, 101. The final preparation had a specific activity of
approximately 500 units per mg protein and, in control experi-
ments, supported only the growth of erythroid colonies or
bursts.
Assays for hematopoietic inhibitory and stimulatory activities
in serum or plasma
The capacity of ESRD patient (N 8) and control (N = 6)
serum or plasma to support or inhibit colony formation was
examined by observing the effect of several concentrations of
serum or plasma on colony growth from autologous marrow
cells. CFU-E- and BFU-E-derived colony growth in the pres-
ence of 5, 10, or 15% test serum plus 15% FCS was compared
to colony growth in the presence of the same total concentra-
tion of FCS alone [10]. In these studies, a suboptimal concen-
tration of Epo (0.3 U/mI) that gave 70% of maximal erythroid
colony and burst growth was used. The capacity of the test
serum to support (or inhibit) erythroid colony growth was
expressed as percent control colony growth [10]:
% Control colony growth =
Number of colonies which
grow in X% test serum + 15% FCS < 100
Number of colonies which
grow in (X + 15)% FCS
Similarly, CFU-GM- and CFU-Meg-derived colony growth in
the presence of 5, 10, or 15% test plasma plus 15% normal
plasma (from a single lot) was compared to colony growth in the
presence of the same total concentration of normal plasma
alone:
% Control colony growth =
Number of colonies which grow in
X% test plasma + 15% normal plasma 100Number of colonies which grow
in (X + l5)% normal plasma
Serum Epo levels
Serum Epo levels were measured by radioimmunoassay
(RIA), as previously described [II].
Data analysis
The Student t-test and the F test for treatment effect of a
repeated measures design were used to determine P values for
statistical significance. The correlation between two parameters
was analyzed by linear regiession.
CFU-E
Results
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The frequencies of hernatopoietic progenitors in non-adher-
ent bone niarrow cells from ESRD patients and normal individ-
uals are shown in Figure I. The numbers of each type of
colony-forming cell varied widely among Ihe subjects in each
group. There were no significant differences (P > 0.1) between
the normal controls, anemic ESRD patients, and non-anemic
ESRD patients in the frequencies of any of the progenitors
assayed. In addition, there were 110 significant differences (P >
0.1) observed between the anephric and nephric ESRD patients
(data not shown).
The serum Epo levels for the ESRD and control subjects are
summarized in Table I. The ESRD patients demonstrated a
much wider range of' Epo levels than the healthy controlsnd
BFU-E
•I-..
S Fig. I. J—Iemnalopoietu progenitor frequencies
There were no significant differences (P >
0.!) observed between the healthy control.
anemic ESRD. and non-anemic ESRD groups.
ESRD ESRD The mean values and standard errors for each
anemic NL HCT group are shown.
two patients with ESRD had serum Epo levels which exceeded
the upper limit of the normal range. However, the mean values
of the ESRD and control groups did not differ significantly (P>
0. I). Five patients with chronic anemia and intact renal function
had serum Epo levels that were significantly higher than nor-
mal. We found no correlation between serum Epo levels and
hematocrit or erythroid progenitor frequency in any of the
study groups (data not shown).
Erythroid progenitors, as they mature, become increasingly
responsive to Epo in terms of their proliferative activity [12].
Therefore, we speculated that the relative proportions of prim-
itive and late erythroid precursor cells should reflect Epo levels
in vivo. Accordingly, we exaniined the ratio of CFU-E fre-
quency to BFU-E frequency for each of the ESRD and control
groups. As we also observed with their serum Epo levels (Table
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N
Epo mU/mi
Mean SEM Range
ESRD, anemic
ESRD, normal Hct
Normal
Non-uremic anemic
11
3
9
5
24
26
20
782
IIa
12
1
600k'
5—137
12—SI
14—23
41—3163
Table 2. The effect of normal or anemic ESRD serum and plasma on
autologous colony growths
Serum
concentration
% Control growth mean si
CFU-E BFU-E
Normal ESRD Normal ESRD
5% 117 26 140 23
[137 291b [87 18]
ill l8 144 25
[106 25] [55 9]
10% 105±9 96±6
[154 28] [118 16]
95±9 113±17
[120 23] [80 12]
15% 104±7 89±5
[153 28] [126 181
102±15 98±10
[121 23] [89 11]
Plasma CFIJ-GM CFIJ-MEG
concentration Normal ESRD Normal ESRD
5% 100 6 114 7
[104± 13] [71±51
121 16 135 28
[13±31 [7±2]
10% 98±3 112±6
[110 15] [72 6]
98±8 93±6
[15 41 [8 2]
15% 98±5 110±6
[109 13] [75 7]
83±5 85±8
[15 41 [8 I]
1), the healthy controls and ESRD patients did not differ
significantly in their CFU-E/BFU-E ratios (Fig. 2). However,
the non-uremic anemic patients that we studied had CFU-
E/BFU-E ratios that were significantly increased (P <0.001) in
comparison to the normal controls and ESRD patients (Fig. 2).
In none of the patient or control groups was there a significant
correlation between serum Epo levels and CFU-E/BFU-E
ratios.
We examined the effect of pre-dialysis anemic ESRD and
normal control serum and plasma on colony growth from
autologous marrow cells. As shown in Table 2, normal and
ESRD sera and plasma were equally supportive of erythroid
and non-erythroid colony growth. We did not observe inhibi-
tion. None of the mean values shown differed significantly from
control colony growth (P > 0.1). Likewise, there were no
significant differences in colony growth (expressed as con-
trol) at any of the serum or plasma concentrations tested (P >
0.1). There was no correlation between the Epo concentrations
of individual serum samples and their capacity to support
CFU-E- or BFU-E-derived colony growth (not shown).
Discussion
The anemia which almost always accompanies ESRD is a
consequence of diminished red blood cell production [1, 2].
Normal ESRD ESRD non-uremic
anemic NL HCT anemic
Fig. 2. CFU-E/BFU-E ratios. CFU-E/BFU-E ratios were significantly
increased (P < 0.001) in the non-uremic anemic individuals compared to
the healthy control and ESRD groups. The mean values and standard
errors for each group are shown.
Impaired production of Epo by damaged kidneys is the primary
determinant of the blunted erythropoietic response [3, 4].
Shortened red cell survival [131, iron deficiency [14], myelofi-
brosis [151, hypersplenism [161, and aluminum toxicity [17] may
also contribute to the development of anemia in some uremic
patients. The role of retained inhibitors of erythropoiesis in the
pathogenesis of this anemia is unclear [51.
In this study, we have utilized in vitro colony-forming assays
to examine hematopoietic progenitor cell frequencies in anemic
and non-anemic ESRD patients and healthy controls. Non-
erythroid as well as erythroid colony-forming cells were as-
sayed to determine the lineage specificity of any observed
changes from normal. In order to investigate how the erythroid
progenitor cell response in vivo might be influenced by Epo
levels, we correlated serum Epo levels, measured by RIA, with
erythroid progenitor cell frequencies.
We found no significant differences between the anemic
ESRD, non-anemic ESRD, and normal control groups in the
frequencies of BFU-E, CFU-E, CFU-GM, or CFU-Meg (Fig.
1). Likewise, we found no significant differences between these
groups in their mean serum Epo levels, although several ESRD
patients had values above or below the normal range (Table 1).
Similar findings with respect to serum Epo levels in uremic
patients have been reported by others [18, 19].
Because the chronic stimulation of endogenous Epo produc-
tion in experimental models of anemia results in an increase in
the numbers of CFU-E but not BFU-E [20], we reasoned that
Table 1. Serum erythropoietin levels
P> 0.1 compared to normal
b P < 0.05 compared to normal
.
P<0.001
.0
U-
U-L)
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0
.
S
S
I.
T.
.
S.
S
S
a Six of the normal controls and eight of the anemic ESRD patients
were studied.
b The values in brackets represent control colony growth expressed
as colonies (mean sEM)/105 marrow cells.
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the relative numbers of late and primitive erythroid progenitors
should reflect Epo levels in vivo. Therefore, we determined
CFU-E/BFU-E ratios in our ESRD patients and healthy con-
trols and correlated these ratios with serum Epo levels. Mean
CFU-E/BFU-E ratios of the ESRD patients and normal con-
trols were not significantly different (Fig. 2). In contrast, a
group of non-uremic anemic patients with elevated serum Epo
levels (Table I) had CFU-E/BFU-E ratios that were signifi-
cantly greater than the ESRD and healthy control groups (Fig.
2). We found no correlation between CFU-E/BFU-E ratios and
serum Epo levels in either patient group or the normal control
group.
Two sets of clinical observations suggest that retained uremic
inhibitors may contribute to the impaired erythropoietic re-
sponse observed in ESRD. First, the institution of chronic
dialysis may be associated with a gradual increase in hemoglo-
bin concentration without effecting an increase in serum Epo
levels [21, 22]. Second, some anemic ESRD patients have
serum Epo levels, measured by RIA or bioassay, that are higher
than normal [18, 19, 22, 231. Some of our data indirectly support
the existence of uremic inhibitors. We observed two uremic
patients, one anemic and the other non-anemic, with elevated
serum Epo levels (137 and 51 mU/mI, respectively) but normal
CFU-E/BFU-E ratios (1.55 and 1.28, respectively). Since we
did not perform simultaneous measurements of Epo levels by
bioassay in these patients, the possibility that our RIA was
detecting immunoreactive but not bioactive Epo cannot be
excluded. However, the sera from these patients did not inhibit
autologous erythroid colony formation in vitro (see below).
The observed decline in erythroid colony growth from mar-
row cells cultured in the presence of either whole uremic serum
or candidate uremic toxins has been cited as evidence support-
ing a pathogenetic role for retained inhibitors [19, 23—26].
However, such studies are compromised by flaws in design.
First, they failed to examine non-erythroid colony growth
concurrently to determine the specificity of potential erythro-
poietic inhibitors. The issue of specificity is important since
leukopenia or thrombocytopenia is seldom seen in anemic
ESRD patients. In fact, we have found that granulocyte-
macrophage and megakaryocyte colony growth from mouse
marrow cells are as sensitive as erythroid colony formation to
the inhibitory effects of uremic serum and the candidate uremic
toxins spermine and spermidine [8, 101. Second, several studies
fail to show that the observed reduction in colony growth in the
presence of uremic serum reflects the presence of inhibitors
rather than a lack of stimulatory factors. Finally, many studies
used heterologous or xenogeneic marrow targets. Interpretation
of the results of such studies might be confounded by the
influence of serum alloantibodies and potentially non-physio-
logical interactions between serum factors and marrow cells
from different species.
In this study, we have assayed uremic serum and plasma for
erythropoietic inhibitors using autologous marrow cells as
target. We examined erythroid and non-erythroid colony growth
concurrently to define the lineage-specificity of any observed
effect. Test sera or plasmas were added to cultures containing
suboptimal concentrations of Epo and FCS or normal plasma.
This strategy permitted the identification of stimulatory as well
as inhibitory effects of test serum and plasma on colony growth
[101. Utilizing this protocol which avoids the shortcomings of
previous studies, we found no evidence for inhibitors of in vitro
hematopolesis in uremic serum and plasma. Pre-dialysis serum
and plasma from anemic ESRD patients were as supportive of
autologous erythroid and non-erythroid colony growth as serum
and plasma from healthy controls and non-anemic ESRD pa-
tients (Table 2). It is possible that this result reflects loss of
inhibitory activity with filtration, heat-inactivation, and/or freezing
of the test samples. This explanation would appear unlikely
since we and others have consistently observed inhibition of
murine colony formation by uremic sera subjected to these
same treatments [10, 19, 23—261. Finally, we observed no
relationship between the Epo concentrations of individual se-
rum samples and their capacity to support CFU-E- or BFU-E-
derived colony growth (not shown).
Careful in vivo studies provide no evidence for the existence
of retained inhibitors of erythroid marrow function. Sheep
rendered uremic, anemic, and dialysis-dependent displayed the
same erythropoietic response to infused Epo-rich sheep plasma
as they did when they were normal [27]. Uremic sheep plasma
does not inhibit autologous hematopoietic colony growth in
vitro [28]. Finally, recombinant human Epo recently has been
shown to fully correct the anemia of ESRD [29, 30]. However,
it is not yet known whether the erythropoietic responses to
recombinant Epo are equivalent in uremic and normal subjects.
If erythropoietic inhibitors can be identified by such studies,
strategies designed to eliminate these substances might result in
more effective Epo therapy.
We conclude that the relative numbers of erythroid and
non-erythroid colony-forming cells are unchanged from normal
in patients with the anemia of ESRD. The normal CFU-E/BFU-
E ratio observed in these patients reflects an inadequate com-
pensatory erythropoietic response due to their inability to
increase Epo production to levels appropriate to their degree of
anemia. Although a few of these patients had elevated serum
Epo levels, we did not detect inhibitors of autologous hemato-
poietic colony formation in uremic serum or plasma. Retained
inhibitors might still play a role in the development of the
anemia of ESRD, but definitive proof of their existence and
pathogenetic significance will require in vivo Epo challenge
studies in normal and uremic subjects.
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